Log in

NYSE:BAXBaxter International Stock Price, Forecast & News

$87.21
-0.10 (-0.11 %)
(As of 07/3/2020 04:00 PM ET)
Add
Compare
Today's Range
$86.93
Now: $87.21
$87.66
50-Day Range
$82.47
MA: $86.44
$90.98
52-Week Range
$69.10
Now: $87.21
$95.19
Volume2.54 million shs
Average Volume3.30 million shs
Market Capitalization$44.23 billion
P/E Ratio26.35
Dividend Yield1.12%
Beta0.84
Baxter International Inc., through its subsidiaries, develops and provides a portfolio of healthcare products. The company operates through North and South America; Europe, Middle East and Africa; and Asia-Pacific segments. The company offers peritoneal dialysis and hemodialysis, and additional dialysis therapies and services; renal replacement therapies and other organ support therapies focused in the intensive care unit; sterile intravenous (IV) solutions, IV therapies, infusion pumps, administration sets, and drug reconstitution devices; and parenteral nutrition therapies. It also provides biological products and medical devices, and surgical hemostat and sealant products used in surgical procedures for hemostasis, tissue sealing, and adhesion prevention; premixed and oncology drug platforms, inhaled anesthesia and critical care products, and pharmacy compounding services; and generic injectable pharmaceuticals. Its products are used in hospitals, kidney dialysis centers, nursing homes, rehabilitation centers, doctors' offices, and by patients at home under physician supervision. The company sells its products through direct sales force, as well as through independent distributors, drug wholesalers, and specialty pharmacy or other alternate site providers in approximately 100 countries. It has an agreement with Celerity Pharmaceutical, LLC to develop acute care generic injectable premix and oncolytic molecules. Baxter International Inc. was founded in 1931 and is headquartered in Deerfield, Illinois.
Read More
Baxter International logo

Beat the Market (BTM) Rank

Analyst Opinion: 3.4Community Rank: 2.7Dividend Strength: 1.7Insider Behavior: 1.0Valuation: 1.3 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

2.00 out of 5 stars


Industry, Sector and Symbol

Industry Surgical & medical instruments
Sub-IndustryHealth Care Equipment
SectorMedical
CUSIP07181310
Phone224-948-2000

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$11.36 billion
Cash Flow$4.97 per share
Book Value$15.50 per share

Profitability

Net Income$1.00 billion

Miscellaneous

Employees50,000
Market Cap$44.23 billion
Next Earnings Date7/23/2020 (Estimated)
OptionableOptionable

Receive BAX News and Ratings via Email

Sign-up to receive the latest news and ratings for BAX and its competitors with MarketBeat's FREE daily newsletter.

Baxter International (NYSE:BAX) Frequently Asked Questions

How has Baxter International's stock been impacted by COVID-19 (Coronavirus)?

Baxter International's stock was trading at $77.97 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization (WHO). Since then, BAX stock has increased by 11.9% and is now trading at $87.21. View which stocks have been most impacted by Coronavirus.

Do Wall Street analysts recommend investors buy shares of Baxter International?

20 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Baxter International in the last year. There are currently 5 hold ratings and 15 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Baxter International.

When is Baxter International's next earnings date?

Baxter International is scheduled to release its next quarterly earnings announcement on Thursday, July 23rd 2020. View our earnings forecast for Baxter International.

How were Baxter International's earnings last quarter?

Baxter International Inc (NYSE:BAX) issued its earnings results on Thursday, April, 30th. The medical instruments supplier reported $0.82 EPS for the quarter, topping analysts' consensus estimates of $0.73 by $0.09. The medical instruments supplier had revenue of $2.80 billion for the quarter, compared to analyst estimates of $2.74 billion. Baxter International had a return on equity of 22.70% and a net margin of 8.85%. The firm's revenue was up 6.2% compared to the same quarter last year. During the same period last year, the firm posted $0.76 EPS. View Baxter International's earnings history.

How often does Baxter International pay dividends? What is the dividend yield for Baxter International?

Baxter International announced a quarterly dividend on Tuesday, May 5th. Stockholders of record on Friday, June 5th will be given a dividend of $0.245 per share on Wednesday, July 1st. This represents a $0.98 dividend on an annualized basis and a dividend yield of 1.12%. The ex-dividend date is Thursday, June 4th. This is a boost from Baxter International's previous quarterly dividend of $0.22. View Baxter International's dividend history.

How will Baxter International's stock buyback program work?

Baxter International declared that its Board of Directors has initiated a share repurchase plan on Tuesday, November 13th 2018, which authorizes the company to repurchase $2,000,000,000.00 in shares, according to EventVestor. This repurchase authorization authorizes the company to purchase up to 6.1% of its shares through open market purchases. Shares repurchase plans are often a sign that the company's board of directors believes its shares are undervalued.

What price target have analysts set for BAX?

20 equities research analysts have issued twelve-month target prices for Baxter International's stock. Their forecasts range from $84.00 to $105.00. On average, they anticipate Baxter International's share price to reach $96.60 in the next twelve months. This suggests a possible upside of 10.8% from the stock's current price. View analysts' price targets for Baxter International.

Has Baxter International been receiving favorable news coverage?

Media stories about BAX stock have been trending negative recently, InfoTrie reports. InfoTrie identifies positive and negative news coverage by analyzing more than six thousand blog and news sources in real-time. The firm ranks coverage of public companies on a scale of negative five to positive five, with scores closest to five being the most favorable. Baxter International earned a news sentiment score of -2.1 on InfoTrie's scale. They also assigned news stories about the medical instruments supplier a news buzz of 0.0 out of 10, meaning that recent news coverage is extremely unlikely to have an effect on the company's share price in the near future. View the latest news about Baxter International.

Are investors shorting Baxter International?

Baxter International saw a increase in short interest in June. As of June 30th, there was short interest totaling 4,030,000 shares, an increase of 31.3% from the June 15th total of 3,070,000 shares. Based on an average daily volume of 3,100,000 shares, the short-interest ratio is presently 1.3 days. Currently, 0.8% of the shares of the stock are short sold. View Baxter International's Current Options Chain.

Who are some of Baxter International's key competitors?

What other stocks do shareholders of Baxter International own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Baxter International investors own include CA (CA), Johnson & Johnson (JNJ), Honeywell International (HON), Cisco Systems (CSCO), AT&T (T), Pfizer (PFE), BlackRock (BLK), Verizon Communications (VZ), Abbott Laboratories (ABT) and Procter & Gamble (PG).

Who are Baxter International's key executives?

Baxter International's management team includes the following people:
  • Mr. José E. Almeida, Chairman, Pres & CEO (Age 57)
  • Mr. James K. Saccaro, Exec. VP & CFO (Age 46)
  • Mr. Sean Martin, Sr. VP & Gen. Counsel (Age 56)
  • Mr. Giuseppe Accogli, Sr. VP & Pres of Americas (Age 48)
  • Mr. Scott Pleau, Sr. VP of Operations (Age 53)

What is Baxter International's stock symbol?

Baxter International trades on the New York Stock Exchange (NYSE) under the ticker symbol "BAX."

Who are Baxter International's major shareholders?

Baxter International's stock is owned by a variety of institutional and retail investors. Top institutional investors include M&R Capital Management Inc. (0.00%). Company insiders that own Baxter International stock include Albert P L Stroucken, Andrew Frye, Carole J Shapazian, Giuseppe Accogli, Jacqueline Kunzler, James R Gavin III, Jeanne K Mason, John D Forsyth, Peter S Hellman, Scott Pleau, Sean Martin, Third Point Llc and Thomas T Stallkamp. View institutional ownership trends for Baxter International.

Which major investors are selling Baxter International stock?

BAX stock was sold by a variety of institutional investors in the last quarter, including M&R Capital Management Inc.. Company insiders that have sold Baxter International company stock in the last year include Albert P L Stroucken, Andrew Frye, Giuseppe Accogli, Jacqueline Kunzler, James R Gavin III, Jeanne K Mason, and John D Forsyth. View insider buying and selling activity for Baxter International.

How do I buy shares of Baxter International?

Shares of BAX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Baxter International's stock price today?

One share of BAX stock can currently be purchased for approximately $87.21.

How big of a company is Baxter International?

Baxter International has a market capitalization of $44.23 billion and generates $11.36 billion in revenue each year. The medical instruments supplier earns $1.00 billion in net income (profit) each year or $3.31 on an earnings per share basis. Baxter International employs 50,000 workers across the globe.

What is Baxter International's official website?

The official website for Baxter International is www.baxter.com.

How can I contact Baxter International?

Baxter International's mailing address is One Baxter Parkway DF2-1W, Deerfield IL, 60015. The medical instruments supplier can be reached via phone at 224-948-2000 or via email at [email protected]

This page was last updated on 7/5/2020 by MarketBeat.com Staff

30 Days of MarketBeat All Access for $1.00

Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools:

  • Best-in-Class Portfolio Monitoring

    View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.

  • Stock Ideas and Recommendations

    Get daily stock ideas top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.

  • Advanced Stock Screeners and Research Tools

    Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your Risk-Free Trial Subscription Here

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.